

# *IFN- $\gamma$ +874 A>T (rs2430561) gene polymorphism and risk of pulmonary tuberculosis: a meta-analysis*

Mohammed Y. Areeshi<sup>1</sup>, Raju K. Mandal<sup>1</sup>, Sajad A. Dar<sup>1,2</sup>, Arshad Jawed<sup>1</sup>, Mohd Wahid<sup>1</sup>, Mohtashim Lohani<sup>3</sup>, Aditya K. Panda<sup>4</sup>, B.N. Mishra<sup>5</sup>, Naseem Akhter<sup>6</sup>, Shafiu Haque<sup>1</sup>

<sup>1</sup>Research and Scientific Studies Unit, College of Nursing and Allied Health Sciences, Jazan University, Jazan, Saudi Arabia

<sup>2</sup>The University College of Medical Sciences and GTB Hospital (University of Delhi), Delhi, India

<sup>3</sup>Department of Emergency Medical Services, College of Applied Medical Sciences, Jazan University, Jazan, Saudi Arabia

<sup>4</sup>Centre for Life Sciences, Central University of Jharkhand, Ranchi, Jharkhand, India

<sup>5</sup>Department of Biotechnology, Institute of Engineering and Technology, Lucknow, Uttar Pradesh, India

<sup>6</sup>Department of Laboratory Medicine, Faculty of Applied Medical Sciences, Albaha University, Albaha, Saudi Arabia

**Corresponding author:**

Dr. Shafiu Haque

Research and Scientific Studies Unit

College of Nursing and Allied Health Sciences

Jazan University

Jazan-45142, Saudi Arabia

Phone/fax: +966-173174383

E-mail:

shafiu.haque@hotmail.com

**Submitted:** 8 March 2017

**Accepted:** 15 October 2017

Arch Med Sci 2021; 17 (1): 177–188

DOI: <https://doi.org/10.5114/aoms.2019.88481>

Copyright © 2019 Termedia & Banach

## Abstract

**Introduction:** The role of interferon gamma (IFN- $\gamma$ ) +874 A>T (rs2430561) gene polymorphism has been evaluated in different ethnicities with pulmonary tuberculosis (PTB) infection, and inconsistent results have been reported. In this study, a meta-analysis was performed to determine the precise association between IFN- $\gamma$  +874 A>T gene polymorphism and PTB susceptibility.

**Material and methods:** A total of 21 studies comprising 4281 confirmed PTB cases and 5186 healthy controls were included in this meta-analysis by searching the PubMed (Medline), EMBASE, and Google Scholar web-databases.

**Results:** We observed reduced risk of PTB in allelic contrast (T vs. A:  $p = 0.001$ ; OR = 0.818, 95% CI: 0.723–0.926), homozygous (TT vs. AA:  $p = 0.017$ ; OR = 0.715, 95% CI: 0.543–0.941), heterozygous (AT vs. AA:  $p = 0.002$ ; OR = 0.782, 95% CI: 0.667–0.917), dominant (TT+AT vs. AA:  $p = 0.002$ ; OR = 0.768, 95% CI: 0.652–0.906), and recessive (TT vs. AA+AT:  $p = 0.042$ ; OR = 0.802, 95% CI: 0.649–0.992) genetic models. In ethnicity-wise subgroup analysis, reduced risk of PTB was found in the Caucasian population. However, we did not find an association with any of the genetic models in the Asian population.

**Conclusions:** In conclusion, the IFN- $\gamma$  +874 A>T gene polymorphism is significantly associated with reduced risk of PTB, showing a protective effect in the overall and in the Caucasian population. However, this polymorphism is not associated with PTB risk in the Asian population.

**Key words:** meta-analysis, interferon- $\gamma$ , pulmonary tuberculosis, polymorphism, genetic model.



## Introduction

Tuberculosis (TB) is chronic infectious disease caused by *Mycobacterium tuberculosis* (*M. tuberculosis*). This is a disease of the lungs, mostly seen in the form of pulmonary type tuberculosis (PTB), which can easily be spread to others by coughing and breathing. Despite the availability of various effective treatment strategies, recent figures from 2014 show that TB is once more on the increase; globally, there is a large burden of the disease with ~9.6 million new cases and ~1.5 million reported deaths [1].

Nearly one-third of the world's population is thought to be affected with *M. tuberculosis*, but a large proportion of the population have no clinical symptoms of the disease. However, the remaining 5–15% of the population is affected with the active disease, as demonstrated by culturable bacilli from the sputum and other clinical symptoms [2]. This indicates that besides the mycobacteria itself, the host genetic factors may also determine the differences in host susceptibility to TB [3]. Earlier reports involving candidate gene approach and genetic association studies have identified various host genetic factors that affect the susceptibility in a variety of diseases [4–6]. So, the identification of host genes and genetic variations that play significant role in susceptibility and resistance to TB would help in understanding the pathogenesis of the disease and perhaps lead to new approaches of treatment or prophylaxis.

Cytokines, and their genes and receptors, have been implicated in the protective immunity, and also associated with pathological severity with altered circulating levels of pro-inflammatory and down-regulatory cytokines in TB [7]. In general, TB infects mainly macrophages in lungs, and Th1-mediated immunity is considered as protective response against *M. tuberculosis*. The human interferon  $\gamma$  gene (*IFN $\gamma$* ) is located on chromosome 12 (12q14) and has four exons spanning about 6 kb. Interferon  $\gamma$  (IFN- $\gamma$ ) encoded by *IFN $\gamma$*  (also called IFNG) is a key T helper (type-1) cytokine produced by natural killer (NK) cells and T cells. The production of IFN- $\gamma$  is essential in innate immunity and plays a pivotal role in macrophage activation for eliminating *Mycobacterium* infection [8]. A previous study reported that malfunction of the *IFN $\gamma$*  gene may lead to infection of *M. tuberculosis* [9]. Single nucleotide polymorphisms (SNPs) present in the promoter or coding regions of cytokine genes result in altered transcriptional function and differential cytokine secretion. Also, the inter-individual variations in IFN- $\gamma$  production are genetically contributed by polymorphisms within the promoter or coding region.

An SNP located in the +874 A>T (rs2430561) position in the first intron of the *IFN- $\gamma$*  gene comprises the binding site for the transcription factor NF $\kappa$ B, which putatively influences the gene expression and secretion of the cytokine, which has a significant impact on infection outcome. It has been reported that TB patients with the homozygous allele A combination produce significantly lower level of IFN- $\gamma$  in comparison to individuals carrying one or two copies of allele T [10]. This polymorphism also displays variable associations with TB disease susceptibility and severity [11]. These studies demonstrated the importance of these cytokines in the development of TB infection and suggested that this genetic variant of the *IFN- $\gamma$*  gene could account for the differences in TB susceptibility.

After considering the functional significance of this genetic variant, a number of case-control studies in recent years have assessed the association of *IFN- $\gamma$*  +874 A>T gene polymorphism with PTB development in different populations. Results from these studies have shown mixed findings, and it is still unclear whether this polymorphism is associated with increased or decreased susceptibility to PTB [10, 12–32]. A probable reason to clarify the noted inconsistencies in the outcomes is the inadequate statistical power of the individual studies in which non-homogenous populations and individuals from different ethnicities were included. To overcome this situation, nowadays a meta-analysis statistical tool is used to explore the risk factors associated with the genetic diseases, as it employs a quantitative method of combining the data drawn from individual studies where sample sizes are too small to produce reliable conclusions [33]. Therefore, we carried out this meta-analysis to assess the effect of *IFN- $\gamma$*  +874 A>T gene polymorphism on the risk of PTB infection.

## Material and methods

### Strategy for literature search

Online web-databases, i.e. PubMed, Medline, EMBASE, and Google Scholar online, were searched for published research articles covering a combination of the following key words: *IFN- $\gamma$* , *IFN $\gamma$*  gene, *IFNG*, interferon gamma gene (polymorphism OR mutation OR variant) AND tuberculosis susceptibility or TB or pulmonary tuberculosis or PTB (last updated on January 2017). We identified the potentially relevant genetic association studies by reading their titles and abstracts, and procured the most pertinent publications matching the pre-eligible criteria for a closer examination. In addition to the above-mentioned online database search, the references given in the selected research arti-

cles were also scrutinised for other potential articles that may have been missed in the preliminary search.

#### Criteria for inclusion and exclusion of the studies

In order to reduce heterogeneity and facilitate the apt interpretation of this pooled analysis, the published articles included in the present meta-analysis had to cover all the given criteria, as follows: a) they had to have reported case-control studies between *IFN- $\gamma$*  +874 A>T gene polymorphism and PTB risk, b) they had to include clearly described confirmed PTB patients and PTB-free controls, d) they had to have available genotype frequency in both the cases and the controls, e) they had to be published in the English language, and f) the data collection and the analysis method had to be acceptable from a statistical point of view. Additionally, when the case-control study was involved in more than one research article using the same case series, we selected the research study that included the largest number of individuals. The major criteria for study exclusion were: a) overlapping or duplicate publication, b) the study-design based on only PTB cases, c) genotype frequency not reported, and d) data from review articles or abstracts.

#### Data extraction

For each retrieved research publication, the methodological quality evaluation and data extraction were independently abstracted in duplicate by two independent investigators (MYA and RKM) using a standard process. Standard data-collection form was used to endorse the precision of the collected data from individual studies by stringently following the pre-set inclusion criteria as mentioned above. The main characteristics abstracted from the retrieved publications comprised the name of the first author, the year of publication, the country of origin, the source of cases and controls, the number of cases and controls, the study type, and the genotype frequencies. Cases related with disagreement/discrepancy on any item of the data from the selected studies were fully deliberated with the investigators to reach a final unanimous agreement. In case failure to reach a consensus between the two investigators, a mutual agreement was attained with an open discussion with the adjudicator (SH).

#### Quality assessment of the selected studies

Methodological quality evaluation of the selected studies was performed independently by two investigators (MYA and RKM) by following the Newcastle-Ottawa Scale (NOS) of quality assess-

ment [34]. The NOS quality assessment criteria included three major aspects: (i) subject selection: 0–4 stars, (ii) comparability of subject: 0–2 stars, and (iii) clinical outcome: 0–3 stars. Selected case-control studies that gained five or more stars were considered as of moderate to good quality [35].


#### Statistical analysis

In this study, the pooled ORs and their corresponding 95% CIs were used to evaluate the strength of the association between *IFN- $\gamma$*  +874 A>T polymorphism and susceptibility to PTB. The heterogeneity assumption was tested by the  $\chi^2$ -based Q-test [36] and was considered statistically significant if the *p*-value was < 0.05 (means Q-test revealed a lack of heterogeneity among the selected studies). The data from single comparisons were pooled using a fixed effects model [37] when no heterogeneity was detected. Otherwise (in case of significant heterogeneity), the random-effects model [38] was applied for pooling of the data (ORs). In order to assess the ethnicity specific effect, sub-group analyses were performed by ethnic group. Furthermore,  $I^2$  statistics was used to measure the inter-study variability ranging between 0 and 100%, wherein 0% indicates no observed heterogeneity and larger values 25%, 50%, and 75%, correspond to small, moderate, and high levels of heterogeneity, respectively [39]. The Hardy-Weinberg equilibrium (HWE) in the control group was calculated using the  $\chi^2$  test. Publication bias was evaluated using the funnel plot, wherein the standard error of log (OR) for each study was plotted against its log (OR) [40]. Furthermore, the Egger's linear regression test was used to measure the association between the mean effect estimate and its variance [41]. The significance of the intercept was measured by the *t*-test considering a *p*-value < 0.05 as a representation of statistically significant publication bias. Before the statistical analysis, a comparative appraisal of 'meta-analysis' software programs was performed by using the web-link: <http://www.meta-analysis.com/pages/comparisons.html>. The Comprehensive Meta-Analysis (CMA) Version 2 software program (Biostat, NJ, USA) was used to perform all the statistical analysis involved in this meta-analysis.

#### Results

##### Characteristics of the studies included in this meta-analysis

A systematic flow-diagram displaying the selection of published studies following the pre-set inclusion and exclusion criteria is shown in Figure 1. After many levels of screening (as per the pre-set



**Figure 1.** PRISMA Flow-diagram showing identification and selection of the studies for this meta-analysis

inclusion and exclusion criteria of study selection) a total of 21 case-control research publications were finally selected after a literature search of the PubMed (Medline), EMBASE, and Google Scholar

web-databases [12–32]. Research publication either reporting *IFN-γ* +874 A>T polymorphism to predict survival in PTB patients or considering genetic variants as indicators for response to therapy were disqualified straightaway. Likewise, studies exploring the levels of *IFN-γ* mRNA or protein expression or pertinent review articles were also eliminated from this study. We incorporated only case-control or cohort design studies mentioning the frequency of all three genotypes. Moreover, the supporting references listed in the retrieved research publications were also scrutinised for other pertinent research publications. After cautious screening, the detailed characteristics of 23 studies from 21 eligible original published research articles included in this meta-analysis are provided in Table I. Distribution of genotypes, HWE *p*-values in the controls, and susceptibility towards PTB are shown in Table II. All the selected 21 studies were inspected for their quality following the Newcastle-Ottawa Scale (NOS) and most of the studies (80%) scored five stars or more, indicating moderate to good quality (Table III).

**Table I.** Main characteristics of all studies included in the meta-analysis

First author and year [Ref. No]	Country	Ethnicity	Control	Cases	Study	Association
Hu <i>et al.</i> , 2015 [12]	China	Asian	480	120	PB	No risk
Mabunda <i>et al.</i> , 2015 [13]	Brazil	Mixed	456	102	HB	No risk
Shen <i>et al.</i> , 2013 [14]	China	Asian	164	69	PB	No risk
Selma <i>et al.</i> , 2011 [15]	Tunisia	African	150	168	HB	AA genotype risk
Hashemi <i>et al.</i> , 2011 [16]	Iran	Asian	166	142	HB	AA genotype risk
Ansari <i>et al.</i> , 2011 [17]	Pakistan	Asian	166	102	PB	No risk
Vallinoto <i>et al.</i> , 2010 [18]	Brazil	Mixed	156	129	HB	No risk
Wang <i>et al.</i> , 2010 [19]	China	Asian	527	522	PB	No risk
Anand <i>et al.</i> , 2010 [20]	India	Asian	66	62	HB	No risk
Ansari <i>et al.</i> , 2009 [21]	Pakistan	Asian	188	111	HB	TT genotype risk
Selvaraj <i>et al.</i> , 2008 [22]	India	Asian	178	160	HB	No risk
Ding <i>et al.</i> , 2008 [23]	China	Asian	310	266	HB	AA genotype risk
Wu <i>et al.</i> , 2008 [24]	China	Asian	111	183	HB	No risk
Hwang <i>et al.</i> , 2007 [25]	Korea	Asian	80	80	HB	No risk
Moran <i>et al.</i> , 2007 [26]	USA	Caucasian	64	139	PB	No risk
Moran <i>et al.</i> , 2007a [26]	USA	African American	174	204	PB	No risk
Moran <i>et al.</i> , 2007b [26]	USA	Hispanics	98	270	PB	No risk
Sallakci <i>et al.</i> , 2007 [27]	Turkey	Caucasian	115	319	PB	TT genotype decreased risk
Cooke <i>et al.</i> , 2006 [28]	West African	African	594	667	PB	No risk
Vidyarani <i>et al.</i> , 2006 [29]	India	Asian	127	129	HB	No risk
Etokebe <i>et al.</i> , 2006 [30]	Croatia	Caucasian	519	179	HB	No risk
López-Maderuelo <i>et al.</i> , 2003 [31]	Spain	Caucasian	100	113	PB	AA genotype risk
Lio <i>et al.</i> , 2002 [32]	Italy	Caucasian	97	45	HB	TT genotype decreased risk

**Table II.** Genotypic distribution of IFN- $\gamma$  +874 A>T (rs2430561) gene polymorphism included in the meta-analysis

First author and year	Controls				Cases				HWE	Power
	Genotype		Minor allele		Genotype		Minor allele			
	AA	AT	TT	MAF	AA	AT	TT	MAF	P-value	
Hu <i>et al.</i> , 2015	212	201	67	0.34	74	36	10	0.23	0.35	0.980
Mabunda <i>et al.</i> , 2014	203	136	21	0.24	66	32	3	0.18	0.08	0.971
Shen <i>et al.</i> , 2013	2	29	133	0.89	0	18	51	0.86	0.01	0.641
Selma <i>et al.</i> , 2011	42	86	22	0.43	77	64	27	0.35	0.26	0.796
Hashemi <i>et al.</i> , 2011	22	111	33	0.53	40	84	18	0.42	0.11	0.781
Ansari <i>et al.</i> , 2011	65	80	21	0.36	30	48	24	0.47	0.04	0.712
Vallinoto <i>et al.</i> , 2010	46	86	24	0.42	73	46	10	0.25	0.01	0.741
Wang <i>et al.</i> , 2010	425	91	10	0.10	427	80	14	0.10	0.28	0.999
Anand <i>et al.</i> , 2010	33	25	8	0.31	28	27	7	0.33	0.13	0.371
Ansari <i>et al.</i> , 2009	76	87	25	0.36	37	47	27	0.45	0.27	0.766
Selvaraj <i>et al.</i> , 2008	79	76	23	0.34	68	72	20	0.35	0.03	0.823
Ding <i>et al.</i> , 2008	164	114	32	0.28	169	81	16	0.21	0.04	0.975
Wu <i>et al.</i> , 2008	91	18	2	0.09	148	32	3	0.10	0.83	0.758
Hwang <i>et al.</i> , 2007	59	21	0	0.13	66	13	1	0.09	0.98	0.460
Moran <i>et al.</i> , 2007	17	31	16	0.49	36	80	23	0.45	0.01	0.571
Moran <i>et al.</i> , 2007a	98	65	11	0.25	120	76	8	0.22	0.95	0.869
Moran <i>et al.</i> , 2007b	62	26	10	0.23	170	82	18	0.21	0.04	0.859
Sallakci <i>et al.</i> , 2007	31	58	26	0.47	115	157	47	0.39	0.47	0.916
Cooke <i>et al.</i> , 2006	415	166	13	0.16	488	159	20	0.14	0.05	0.999
Vidyarani <i>et al.</i> , 2006	55	52	20	0.36	61	54	14	0.31	0.91	0.689
Etokebe <i>et al.</i> , 2006	134	282	103	0.47	50	92	37	0.46	0.06	0.992
López-Maderuelo <i>et al.</i> , 2003	31	50	19	0.44	62	40	11	0.27	0.07	0.595
Lio <i>et al.</i> , 2002	25	47	25	0.50	11	30	4	0.42	0.07	0.410

MAF – minor allele frequency, HWE – Hardy-Weinberg equilibrium.

### Publication bias

Begg's funnel plot and Egger's test were applied to appraise the publication bias of the included studies. The shape of the funnel plot was almost symmetric (Supplementary Figure S1). The Egger's test did not show any evidence of publication bias (Table IV).

### Heterogeneity analysis

In order to check heterogeneity among the selected studies, Q-test and  $I^2$  statistics were used. The analysis revealed the presence of significant heterogeneity in all the models. Thus, a random effects model was applied to synthesise the data (Table IV) (Supplementary Figure S1).

### Sensitivity analysis

Sensitivity analysis was done to examine the effect of each individual study on the pooled OR by deleting a single study each time. The results

revealed that no individual study affected the pooled OR significantly, suggesting stability of this meta-analysis (Figures 2 A, B).

### Quantitative synthesis

All the 21 studies (yielding 23 case-control study groups) had desired data, conclusively of 4281 confirmed PTB cases and 5186 healthy controls, to calculate the pooled ORs. The results of pooled study demonstrated that *IFN- $\gamma$  +874 A>T* polymorphism is associated with reduced risk of PTB susceptibility (protective effect) in the general population under all the genetic models, i.e. allelic contrast (T vs. A:  $p = 0.001$ ; OR = 0.818, 95% CI: 0.723–0.926), homozygous (TT vs. AA:  $p = 0.017$ ; OR = 0.715, 95% CI: 0.543–0.941), heterozygous (AT vs. AA:  $p = 0.002$ ; OR = 0.782, 95% CI: 0.667–0.917), dominant (TT+AT vs. AA:  $p = 0.002$ ; OR = 0.768, 95% CI: 0.652–0.906), and recessive (TT vs. AA+AT:  $p = 0.042$ ; OR = 0.802, 95% CI: 0.649–0.992) genetic models (Figures 3 A, B).

**Table III.** Quality assessment conducted according to the Newcastle-Ottawa Scale for all studies included in the meta-analysis

First author and year	Quality indicators		
	Selection	Comparability	Exposure
Hu <i>et al.</i> , 2015	***	*	*
Mabunda <i>et al.</i> , 2015	***	*	**
Shen <i>et al.</i> , 2013	****	*	**
Selma <i>et al.</i> , 2011	***	*	**
Hashemi <i>et al.</i> , 2011	***	*	**
Ansari <i>et al.</i> , 2011	***	*	**
Vallinoto <i>et al.</i> , 2010	****	**	**
Wang <i>et al.</i> , 2010	****	*	**
Anand <i>et al.</i> , 2010	***	*	**
Ansari <i>et al.</i> , 2009	***	*	**
Selvaraj <i>et al.</i> , 2008	***	*	***
Ding <i>et al.</i> , 2008	***	*	**
Wu <i>et al.</i> , 2008	****	**	***
Hwang <i>et al.</i> , 2007	***	*	***
Moran <i>et al.</i> , 2007	***	*	***
Sallakci <i>et al.</i> , 2007	****	**	**
Cooke <i>et al.</i> , 2006	***	*	**
Vidyarani <i>et al.</i> , 2006	***	*	***
Etokebe <i>et al.</i> , 2006	***	*	**
López-Maderuelo <i>et al.</i> , 2003	****	*	**
Lio <i>et al.</i> , 2002	***	*	**

### Subgroup analysis

A subgroup analysis based on ethnicity (case-control study population under consideration) was also performed to explore its effect (Asian and Caucasian) on the association between *IFN-γ +874 A>T* and PTB risk.

### Subgroup analysis of the Asian population

Out of 21 studies included for overall meta-analysis, 12 studies were of Asian populations and were included in the subgroup analysis. Significant heterogeneity was found in all the genetic models (Table V) (Supplementary Figure S2). So, random effect models were applied for the analyses. Overall, no significant association of *IFN-γ +874 A>T* SNP and PTB susceptibility was found in all the genetic models, i.e. allele (T vs. A:  $p = 0.292$ ; OR = 0.899, 95% CI: 0.738–1.096), homozygous (TT vs. AA:  $p = 0.325$ ; OR = 0.885, 95% CI: 0.693–1.129), heterozygous (AT vs. AA:  $p = 0.100$ ; OR = 0.838, 95% CI: 0.679–1.034), dominant (TT+AT vs. AA:  $p = 0.199$ ; OR = 0.854, 95% CI: 0.670–1.087), and recessive (TT vs. AA+AT:  $p = 0.679$ ; OR = 0.932, 95% CI: 0.670–1.298) genetic models (Figure 4).

### Subgroup analysis of the Caucasian population

In the Caucasian population five studies were included for subgroup analysis. No significant publication bias and heterogeneity was noticed (Supplementary Figure S3), and thus fixed effect models were applied for all the genetic models (Table VI). Interestingly, we found significantly decreased risk of PTB (in relation with *IFN-γ +874 A>T* SNP) in allele (T vs. A:  $p = 0.001$ ; OR = 0.782, 95% CI: 0.672–0.909), homozygous (TT vs. AA:  $p = 0.003$ ; OR = 0.615, 95% CI: 0.448–0.844), dominant (TT+AT vs. AA:  $p = 0.010$ ; OR = 0.735, 95% CI: 0.582–0.929), and recessive (TT vs. AA+AT:  $p = 0.011$ ; OR = 0.701, 95% CI: 0.533–0.921) genetic models (Figure 5). However, the heterozygous model (AT vs. AA:  $p = 0.070$ ; OR = 0.796, 95% CI: 0.622–1.019) did not show any risk of PTB in relation to *IFN-γ +874 A>T* SNP (Figure 5).


### Discussion

The cytokine network plays an important role in homeostasis of the immune response. Genetic variations in cytokine genes have been described earlier and demonstrated to influence gene transcription, leading to inter-individual variations in cytokines and may result in abnormal or aberrant immune response, as seen in *M. tuberculosis* infection [42]. Various mechanisms have been described for the development of a protective immunity that prevents the progression of the active disease [43]. The candidate gene approach and association studies have identified various host genetic factors that affect the susceptibility to TB [43].


An earlier report demonstrated that immuno-regulatory genes are important in modulating the host susceptibility to PTB because the first line of defence against *M. tuberculosis* involves the iden-

**Table IV.** Statistics to test publication bias and heterogeneity in the meta-analysis: overall population

Comparisons	Egger's regression analysis			Heterogeneity analysis			Model used for the meta-analysis
	Intercept	95% Confidence interval	P-value	Q-value	Pheterogeneity	I <sup>2</sup> (%)	
T vs. A	-0.64	-3.45 to 2.16	0.63	60.91	0.001	63.88	Random
TT vs. AA	-0.22	-2.34 to 1.89	0.82	52.84	0.001	58.37	Random
AT vs. AA	0.41	-1.56 to 2.38	0.66	49.29	0.001	55.37	Random
TT+AT vs. AA	0.01	-2.16 to 2.18	0.99	59.02	0.001	62.72	Random
TT vs. AA+AT	-0.76	-2.68 to 1.15	0.41	40.44	0.010	45.60	Random



**Figure 2. A** – Sensitivity analysis to evaluate the influence of each study on the pooled OR by deleting a single study each time for the overall analysis (allelic contrast (T vs. A), homozygous (TT vs. AA) and heterozygous (AT vs. AA) genetic models). Black squares represent the value of OR, and the size of the square indicates the inverse proportion relative to its variance. The horizontal line is the 95% CI of OR. **B** – Sensitivity analysis to evaluate the influence of each study on the pooled OR by deleting a single study each time for the overall analysis (dominant (TT+AT vs. AT) and recessive (TT vs. AA+AT) genetic models). The black squares represent the value of OR, and the size of the square indicates the inverse proportion relative to its variance. The horizontal line is the 95% CI of OR



**Figure 3.** A – Forest plot of OR with 95% CI of PTB risk associated with the IFN- $\gamma$  +874 A>T gene polymorphism for overall population (allelic contrast (T vs. A), homozygous (TT vs. AA), heterozygous (AT vs. AA) genetic models). The black square represents the value of OR, and the size of the square indicates the inverse proportion relative to its variance. The horizontal line is the 95% CI of OR. B – Forest plot of OR with 95% CI of PTB risk associated with the IFN- $\gamma$  +874 A>T gene polymorphism for the overall population (dominant (TT+AT vs. AT), recessive (TT vs. AA+AT) genetic models). The black square represents the value of OR, and the size of the square indicates the inverse proportion relative to its variance. The horizontal line is the 95% CI of OR

tification and uptake of the bacterium by macrophages and dendritic cells [44]. IFN- $\gamma$  is a potent activator of macrophages, and clinical and experimental evidence showed that IFN- $\gamma$  plays a key role in antimicrobial activities that regulate mycobacterial infection. In recent years, IFN- $\gamma$  +874 A>T gene polymorphism has been widely studied for potential association with increased/reduced/no risk of PTB, but the findings were inconsistent, and still the precise association between the IFN- $\gamma$  +874 A>T SNP and PTB risk is inconclusive. This inconclusive finding warranted further studies

with large sample sizes for accurate estimation of the association between the IFN- $\gamma$  +874 A>T gene polymorphism and PTB disease. Hence, in order provide a precise conclusion against the above-mentioned controversial results, a meta-analysis is thought to be needed to achieve more reliable and accurate statistical evidence on the association between IFN- $\gamma$  +874 A>T SNP and PTB susceptibility. The pooled ORs generated from a large sample size and sufficient statistical power from various studies have the power to reduce the random errors [45].

**Table V.** Statistics to test publication bias and heterogeneity in the meta-analysis: Asian population

Comparisons	Egger's regression analysis			Heterogeneity analysis			Model used for the meta-analysis
	Intercept	95% Confidence interval	P-value	Q-value	Pheterogeneity	I <sup>2</sup> (%)	
T vs. A	0.57	-3.97 to 5.12	0.78	36.02	0.001	69.46	Random
TT vs. AA	0.58	-2.50 to 3.68	0.68	35.57	0.001	66.23	Random
AT vs. AA	0.81	-1.76 to 3.35	0.49	19.92	0.046	44.77	Random
TT+AT vs. AA	0.73	-2.32 to 3.79	0.60	29.05	0.002	62.14	Random
TT vs. AA+AT	0.376	-2.72 to 3.47	0.79	23.46	0.015	53.11	Random

We included 23 case-control group studies from 21 published articles complying with all the eligible criteria. All the included studies scored five or more stars in NOS quality assessment and indicated good to moderate quality by clearly stating the sample size, genotype, and inclusion criteria of PTB patients and healthy controls. We found that pooled results of *IFN- $\gamma$*  +874 A>T gene polymorphism for each genetic model as well as the allele contrast was significantly associated with decreased risk of PTB. These observations lead to the conclusion that that *IFN- $\gamma$*  +874 A>T polymorphism leads to a protective role in PTB infection. This finding highlights that *IFN- $\gamma$*  +874 A>T polymorphism may be an important marker with possible relevant application when dealing with the prognosis of PTB. An earlier meta-analysis also indicated a protective role of *IFN- $\gamma$*  +874 A>T gene polymorphism in TB disease, based on only 11 studies [11] (case-control series) due to the limited availability of the data at that time, with no clear-cut differentiation of overall TB into PTB and extra-pulmonary TB, and lack of subgroup analysis.


The importance of *IFN- $\gamma$*  in TB has been difficult to establish. *IFN- $\gamma$*  is critical to activation of macrophages during mycobacterial infection. Certainly, many studies have shown that the levels of *IFN- $\gamma$*  are lower in subjects with active TB than in controls, suggesting a protective role of this cytokine [8].

The genotype frequency of *IFN- $\gamma$*  +874 A>T vary greatly in different ethnicities. Previous studies have shown that there is a discrepancy in TB susceptibility among different ethnicities [46]. Hence, we conducted subgroup analysis by ethnicity, and our results showed that the *IFN- $\gamma$*  +874 A>T genotype is significantly associated with decreased PTB risk in the Caucasian population and provides a protective effect. Whereas, no significant association between *IFN- $\gamma$*  +874 A>T and PTB susceptibility was found in the Asian ethnic population. In this manner, our subgroup analysis at least presents evidence for the racial differences of *IFN- $\gamma$*  +874 A>T polymorphism and its effects. However,

TB susceptibility genes in genome-wide screens endorsed the possibility of multigenic predisposition of TB [47, 48]. However, due to the multifactorial nature of TB infection and complex nature of the immune system, *IFN- $\gamma$*  +874 A>T gene polymorphism cannot be solely accountable for the predisposition of PTB.


In this study, significant heterogeneity was found between the selected studies during the heterogeneity evaluation. This limitation was in line with a previously published meta-analysis, which reported significant heterogeneity across the studies under consideration [11]. This may be due to some factors, e.g. the ethnicity, selection of method, the definition of cases, and the sample size. However, our study has some limitations, hence it is worth mentioning for their redressal in future studies. First, we only selected studies published in the English language, abstracted and indexed by the specific web-databases for data analysis; it is possible that some relevant studies published in other languages and abstracted and indexed in other databases may have been missed. Second, the extrapolated data were not stratified by other factors, e.g. HIV infection status or severity of the PTB infection, and these results are based on the above-mentioned unadjusted parameters. Infection is the 'combine effect' of the interaction between the host, the parasite, and the environment, and is superimposed on the continual evolution and adaptation of the microbial and human genomes to each other [49]. Third, we failed to test gene-gene and gene-environment interactions, due to lack of adequate data available in the published reports; the interaction of different susceptibility genes and environmental factors can lead to the disease.

Notwithstanding the above limitations, there are some advantages associated with our study. First, this meta-analysis included a greater number of studies (which were not incorporated earlier) to increase the statistical power and attain robust conclusions. Second, publication bias did not exist, and sensitivity analysis also aided the



**Figure 4.** Forest plots of ORs with 95% CI of PTB risk associated with the IFN- $\gamma$  +874 A>T gene polymorphism in the Asian population (allelic contract (T vs. A), homozygous (TT vs. AA), heterozygous (AT vs. AA), dominant (TT+AT vs. AT), recessive (TT vs. AA+AT) genetic models). The black square represents the value of OR, and the size of the square indicates the inverse proportion relative to its variance. The horizontal line is the 95% CI of OR

authenticity of our results. In addition, all the included studies were of good to moderate quality, fulfilling the pre-set criteria for study inclusion as tested by the NOS quality assessment scale.



**Figure 5.** Forest plots of ORs with 95% CI of PTB risk associated with the IFN- $\gamma$  +874 A>T gene polymorphism in the Caucasian population (allelic contract (T vs. A), homozygous (TT vs. AA), heterozygous (AT vs. AA), dominant (TT+AT vs. AT), recessive (TT vs. AA+AT) genetic models). The black square represents the value of OR, and the size of the square indicates the inverse proportion relative to its variance. The horizontal line is the 95% CI of OR

In conclusion, that *IFN-γ* +874 A>T gene polymorphism is significantly associated with decreased risk of PTB, showing a protective effect in the overall and in the Caucasian population. Whereas, +874 A>T polymorphism of *IFN-γ* gene is not associated with increased/decreased risk of PTB in the Asian population. As the immune response in PTB infection is polygenic in nature, further larger clinical and laboratory studies are warranted to improve our understanding of the mechanism of the cytokine gene in such a complex disease. This will help in the identification of host immunogenetic factors responsible for PTB susceptibility, which may help in the controlling of this infectious disease.

**Table VI.** Statistics to test publication bias and heterogeneity in the meta-analysis: Caucasian population

Comparisons	Egger's regression analysis			Heterogeneity analysis			Model used for the meta-analysis
	Intercept	95% Confidence Interval	P-value	Q-value	Heterogeneity	I <sup>2</sup> (%)	
T vs. A	-3.04	-10.89 to 4.81	0.305	9.415	0.052	57.51	Fixed
TT vs. AA	-2.83	-8.13 to 2.45	0.186	7.332	0.119	45.44	Fixed
AT vs. AA	1.33	-7.88 to 10.55	0.675	8.721	0.068	54.13	Fixed
TT+AT vs. AA	0.14	-9.36 to 9.65	0.963	8.842	0.065	54.76	Fixed
TT vs. AA+AT	-3.63	-6.52 to -0.75	0.027	7.780	0.100	48.58	Fixed

## Acknowledgments

The authors are thankful to the Deanship Scientific Research, Jazan University, Jazan-45142, Saudi Arabia for providing the necessary dry lab facilities for this research study.

Mohammed Y. Areeshi and Raju K. Mandal contributed equally to this work.

## Conflict of interest

The authors declare no conflict of interest.

## References

- World Health Organization, Global Tuberculosis Report, 2015. Available at: [http://apps.who.int/iris/bitstream/10665/191102/1/9789241565059\\_eng.pdf?ua=1](http://apps.who.int/iris/bitstream/10665/191102/1/9789241565059_eng.pdf?ua=1).
- Schluger NW. Recent advances in our understanding of human host responses to tuberculosis. *Respir Res* 2001; 2: 157-63.
- Bellamy R. Susceptibility to Mycobacterial infections: the importance of host genetics. *Genes Immun* 2003; 4: 4-11.
- Kiliszek M, Kozluk E, Franaszczyk M, et al. The 4q25, 1q21, and 16q22 polymorphisms and recurrence of atrial fibrillation after pulmonary vein isolation. *Arch Med Sci* 2016; 12: 38-44.
- Mlak R, Homa-Mlak I, Powrózka T, et al. Impact of I/D polymorphism of ACE gene on risk of development and course of chronic obstructive pulmonary disease. *Arch Med Sci* 2016; 12: 279-87.
- Ozdemirkiran FG, Nalbantoglu S, Gokgoz Z, et al. FAS/FASL gene polymorphisms in Turkish patients with chronic myeloproliferative disorders. *Arch Med Sci* 2017; 13: 426-32.
- Ferraz JC, Melo FB, Albuquerque MF, Montes C, Abath FG. Immune factors and immunoregulation in tuberculosis. *Braz J Med Biol Res* 2006; 39: 1387-97.
- Condos R, Rom WN, Liu YM, Schluger NW. Local immune responses correlate with presentation and outcome in tuberculosis. *Am J Respir Crit Care Med* 1998; 157: 729-35.
- Ottenhoff TH, Kumararatne D, Casanova JL. Novel human immunodeficiencies reveal the essential role of type-I cytokines in immunity to intracellular bacteria. *Immunol Today* 1998; 19: 491-4.
- Lopez-Maderuelo D, Arnalich F, Serantes R, et al. Interferon-gamma and interleukin-10 gene polymorphisms in pulmonary tuberculosis. *Am J Respir Crit Care Med* 2003; 167: 970-5.
- Pacheco AG, Cardoso CC, Moraes MO. IFNG +874 T/A, IL10-1082 G/A and TNF -308G/A polymorphisms in association with tuberculosis susceptibility: a meta-analysis study. *Hum Genet* 2008; 123: 477-84.
- Hu Y, Wu L, Li D, Zhao Q, Jiang W, Xu B. Association between cytokine gene polymorphisms and tuberculosis in a Chinese population in Shanghai: a case-control study. *BMC Immunol* 2015; 16: 8.
- Mabunda N, Alvarado-Arnez LE, Vubil A, et al. Gene polymorphisms in patients with pulmonary tuberculosis from Mozambique. *Mol Biol Rep* 2015; 42: 71-6.
- Shen C, Jiao WW, Feng WX, et al. IFNG polymorphisms are associated with tuberculosis in Han Chinese pediatric female population. *Mol Biol Rep* 2013; 40: 5477-82.
- Selma BW, Harizi H, Bougmiza I, et al. Interferon gamma +874 T/A polymorphism is associated with susceptibility to active pulmonary tuberculosis development in Tunisian patients. *DNA Cell Biol* 2011; 30: 379-87.
- Hashemi M, Sharifi-Mood B, Nezamdoost M, et al. Functional polymorphism of interferon- $\gamma$  (IFN- $\gamma$ ) gene +874T/A polymorphism is associated with pulmonary tuberculosis in Zahedan, Southeast Iran. *Prague Med Rep* 2011; 112: 38-43.
- Ansari A, Hasan Z, Dawood G, Hussain R. Differential combination of cytokine and interferon- $\gamma$  +874 T/A polymorphisms determines disease severity in pulmonary tuberculosis. *PLoS One* 2011; 6: e27848.
- Vallinoto AC, Graça ES, Araújo MS, et al. IFNG +874T/A polymorphism and cytokine plasma levels are associated with susceptibility to *Mycobacterium tuberculosis* infection and clinical manifestation of tuberculosis. *Hum Immunol* 2010; 71: 692-6.
- Wang J, Tang S, Shen H. Association of genetic polymorphisms in the IL12-IFNG pathway with susceptibility to and prognosis of pulmonary tuberculosis in a Chinese population. *Eur J Clin Microbiol Infect Dis* 2010; 29: 1291-5.
- Anand PS, Harishankar M, Selvaraj P. Interferon gamma gene +874 A/T polymorphism and intracellular interferon gamma expression in pulmonary tuberculosis. *Cytokine* 2010; 49: 130-3.
- Ansari A, Talat N, Jamil B, et al. Cytokine gene polymorphisms across tuberculosis clinical spectrum in Pakistani patients. *PLoS One* 2009; 4: e4778.
- Selvaraj P, Alagarasu K, Harishankar M, Vidyarani M, Nisha Rajeswari D, Narayanan PR. Cytokine gene polymorphisms and cytokine levels in pulmonary tuberculosis. *Cytokine* 2008; 43: 26-33.
- Ding S, Li L, Zhu X. Polymorphism of the interferon-gamma gene and risk of tuberculosis in a southeastern Chinese population. *Hum Immunol* 2008; 69: 129-33.
- Wu F, Qu Y, Tang Y, Cao D, Sun P, Xia Z. Lack of association between cytokine gene polymorphisms and silicosis and pulmonary tuberculosis in Chinese iron miners. *J Occup Health* 2008; 50: 445-54.

25. Hwang JH, Kim EJ, Kim SY, et al. Polymorphisms of interferon-gamma and interferon-gamma receptor 1 genes and pulmonary tuberculosis in Koreans. *Respirology* 2007; 12: 906-10.
26. Moran A, Ma X, Reich RA, Graviss EA. No association between the +874 T/A single nucleotide polymorphism in the IFN-gamma gene and susceptibility to TB. *Int J Tuberc Lung Dis* 2007; 11: 113-5.
27. Sallakci N, Coskun M, Berber Z, et al. Interferon-gamma gene+874 T-A polymorphism is associated with tuberculosis and gamma interferon response. *Tuberculosis (Edinb)* 2007; 87: 225-30.
28. Cooke GS, Campbell SJ, Sillah J, et al. Polymorphism within the interferon-gamma/receptor complex is associated with pulmonary tuberculosis. *Am J Respir Crit Care Med* 2006; 174: 339-43.
29. Vidyarani M, Selvaraj P, Prabhu Anand S, Jawahar MS, Adhilakshmi AR, Narayanan PR. Interferon gamma (IFN gamma) & interleukin-4 (IL-4) gene variants & cytokine levels in pulmonary tuberculosis. *Indian J Med Res* 2006; 124: 403-10.
30. Etokebe GE, Bulat-Kardum L, Johansen MS, et al. Interferon-gamma gene (T874A and G2109A) polymorphisms are associated with microscopy-positive tuberculosis. *Scand J Immunol* 2006; 63: 136-41.
31. López-Maderuelo D, Arnalich F, Serantes R, et al. Interferon-gamma and interleukin-10 gene polymorphisms in pulmonary tuberculosis. *Am J Respir Crit Care Med* 2003; 167: 970-5.
32. Lio D, Marino V, Serauto A, et al. Genotype frequencies of the +874T->A single nucleotide polymorphism in the first intron of the interferon-gamma gene in a sample of Sicilian patients affected by tuberculosis. *Eur J Immunogenet* 2002; 29: 371-4.
33. Sheng WY, Yong Z, Yun Z, Hong H, Hai LL. Toll-like receptor 4 gene polymorphisms and susceptibility to colorectal cancer: a meta-analysis and review. *Arch Med Sci* 2015; 11: 699-707.
34. Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. *Eur J Epidemiol* 2010; 25: 603-5.
35. Hu P, Huang MY, Hu XY, et al. Meta-analysis of C242T polymorphism in CYBA genes: risk of acute coronary syndrome is lower in Asians but not in Caucasians. *J Zhejiang Univ Sci B* 2015; 16: 370-9.
36. Wu R, Li B. A multiplicative-epistatic model for analyzing interspecific differences in outcrossing species. *Biometrics* 1999; 55: 355-65.
37. Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. *J Natl Cancer Inst* 1959; 22: 719-48.
38. DerSimonian R, Laird N. Meta-analysis in clinical trials. *Control Clin Trials* 1986; 3: 177-88.
39. Higgins JP, Thompson SG, Deeks JJ, et al. Measuring inconsistency in meta-analyses. *BMJ* 2003; 327: 557-60.
40. Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. *Biometrics* 1994; 50: 1088-101.
41. Egger M, Davey Smith G, Schneider M, et al. Bias in metaanalysis detected by a simple, graphical test. *BMJ* 1997; 315: 629-34.
42. Flynn JL, Chan J. Immunology of tuberculosis. *Annu Rev Immunol* 2001; 19: 93-129.
43. Moller M, de Wit E, Hoal EG. Past, present and future directions in human genetic susceptibility to tuberculosis. *FEMS Immunol Med Microbiol* 2010; 58: 3-26.
44. Rockett KA, Brookes R, Udalova I, et al. 1,25-Dihydroxyvitamin D3 induces nitric oxide synthase and suppresses growth of *Mycobacterium tuberculosis* in a human macrophage-like cell line. *Infect Immun* 1998; 66: 5314-21.
45. Ioannidis JP, Boffetta P, Little J, et al. Assessment of cumulative evidence on genetic associations: interim guidelines. *Int J Epidemiol* 2008; 37: 120-32.
46. Racial differences in susceptibility to infection by *Mycobacterium tuberculosis*. *N Engl J Med* 1990; 322: 422-7.
47. Bellamy R. Genome-wide approaches to identifying genetic factors in host susceptibility to tuberculosis. *Microbes Infect* 2006; 8: 1119-23.
48. Cervino AC, Lakiss S, Sow O, et al. Fine mapping of a putative tuberculosis-susceptibility locus on chromosome 15q11-13 in African families. *Hum Mol Genet* 2002; 11: 1599-1603.
49. Petri WA, Beth D, Patrick K, Haque R, Duggal P. Genes influencing susceptibility to infection. *J Infect Dis* 2008; 197: 4-6.